A
Alberto Bortolami
Publications - 3
Citations - 98
Alberto Bortolami is an academic researcher. The author has contributed to research in topics: Clinical trial & Randomized controlled trial. The author has an hindex of 2, co-authored 3 publications receiving 23 citations.
Papers
More filters
Journal ArticleDOI
Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer.
Giulia Pasello,Alberto Pavan,Ilaria Attili,Alberto Bortolami,Laura Bonanno,Jessica Menis,Pierfranco Conte,Valentina Guarneri +7 more
TL;DR: The present review focuses on RWE about ICIs in lung cancer treatment, with particular reference to special patient populations, and discusses potential application of real-world data in a potential innovative drug development model.
Journal ArticleDOI
Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in Italy
Valentina Guarneri,Paolo Pronzato,Oscar Bertetto,Fausto Roila,Gianni Amunni,Alberto Bortolami,Sandro Tognazzo,Gaia Griguolo,Eva Pagano,Fabrizio Stracci,Fortunato Bianconi,Fabrizio Gemmi,Letizia Bachini,Giovannino Ciccone,Gabriella Paoli,Laura Paleari,Pierfranco Conte +16 more
TL;DR: Evaluating the quality of BC care at a population level is possible and potentially useful for guiding quality improvement interventions, despite highlighting some limitations in the use of administrative data to measure health care performance.
Journal ArticleDOI
From Diagnostic‐Therapeutic Pathways to Real‐World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR‐Positive Non‐Small Cell Lung Cancer (MOST Study)
Giulia Pasello,Giovanni Vicario,Fable Zustovich,Francesco Oniga,Stefania Gori,Francesco Rosetti,Andrea Bonetti,Adolfo Favaretto,Silvia Toso,Roberta Redelotti,Antonio Santo,Daniele Bernardi,Petros Giovanis,Cristina Oliani,Lorenzo Calvetti,Carlo Gatti,Giovanni Palazzolo,Zora Baretta,Alberto Bortolami,Laura Bonanno,Marco Basso,Jessica Menis,Donatella Da Corte,Stefano Frega,Valentina Guarneri,Pierfranco Conte +25 more
TL;DR: Good regional adherence and compliance to the diagnostic-therapeutic pathway defined for patients with nonsquamous NSCLC was shown, and the budget impact analysis suggests the potential application of real-world data in the process of drug price negotiation.